Symbol | Exchange | Currency |
|---|
Pre-Open Stock Movers: Antares Pharma, Inc. (NASDAQ:ATRS) 49% HIGHER; Halozyme Therapeutics, Inc. (NASDAQ:HALO) agreed to acquire the company for $5.60 per share in cash, or $960...
After-Hours Stock Movers: NanoString Technologies Inc (NASDAQ:NSTG) 29% LOWER; announced preliminary total product and service revenue of approximately $31 million for the first...
Trovagene, Inc. (NASDAQ:TROV) announced successful completion of a phase Ib dose escalation study evaluating its sole pipeline candidate, onvansertib, in combination with...
San Diego, CA-based TrovaGene Inc. (NASDAQ:TROV) , a molecular diagnostic company, recently announced encouraging data pertaining to its Precision Cancer Monitoring (PCM)...
TrovaGene Inc. (NASDAQ:TROV) is expected to release second-quarter 2016 results on Aug 4. Last quarter, the company reported a loss of 38 cents per share, which was wider than...
Cardiff Oncology Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatment for cancer patients. Its drug candidate onvansertib, is a polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. Its clinical trial includes TROV-054, CRDF-001 and TROV-053. TROV-054 is a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and Avastin (bevacizumab). TROV-053 is a Phase II open-label clinical trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone. CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin, and fluorouracil for second line treatment of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
| Average | 8.000 (+288.350% Upside) |
| High | 14.000 |
| Low | 5.000 |
| Price | 2.060 |
| No. of Analysts | 3 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 152.29 | 152.93 | 150.66 | +0.56 | +0.37% | 16.93M | NASDAQ | |||
| 104.30 | 104.32 | 103.28 | +0.27 | +0.26% | 1.06M | NYSE | |||
| 99.16 | 101.58 | 98.27 | -3.02 | -2.96% | 27.70M | NASDAQ | |||
| 261.97 | 263.45 | 260.08 | +5.20 | +2.03% | 10.11M | NASDAQ | |||
| 3.41 | 3.88 | 3.07 | -2.45 | -41.82% | 105.27M | NASDAQ | |||
| 139.74 | 140.11 | 139.10 | -1.66 | -1.17% | 1.16M | NYSE | |||
| 188.46 | 189.12 | 184.40 | +2.40 | +1.29% | 8.32M | NASDAQ | |||
| 43.68 | 43.94 | 43.66 | -0.08 | -0.18% | 4.92M | NYSE | |||
| 123.70 | 124.46 | 123.42 | -2.03 | -1.61% | 867.48K | NYSE | |||
| 104.49 | 104.66 | 103.12 | +1.59 | +1.54% | 8.03M | NASDAQ | |||
| 59.99 | 60.15 | 59.60 | -0.17 | -0.29% | 2.45M | NYSE | |||
| 213.78 | 214.38 | 211.50 | +2.89 | +1.37% | 10.47M | NASDAQ | |||
| 73.77 | 75.78 | 71.90 | +4.68 | +6.78% | 4.53M | NYSE | |||
| 50.51 | 51.79 | 50.18 | -1.06 | -2.06% | 3.58M | NYSE | |||
| 105.06 | 107.34 | 104.43 | -0.39 | -0.37% | 4.11M | NYSE |